Skip to main content
Top
Published in: Tumor Biology 4/2010

01-08-2010 | Research Article

Tumor markers AFP, CA 125, and CA 19-9 in the long-term follow-up of sacrococcygeal teratomas in infancy and childhood

Authors: Satu-Liisa Pauniaho, Olga Tatti, Pekka Lahdenne, Harry Lindahl, Mikko Pakarinen, Risto Rintala, Markku Heikinheimo

Published in: Tumor Biology | Issue 4/2010

Login to get access

Abstract

Given the tendency of a proportion of sacrococcygeal teratomas (SCT) to recur, we evaluated whether serial tumor marker measurements are helpful in the management of these children. Between 1985 and 2006, 32 children with SCT were followed up for 1–15 years, and a total of 344, 197, and 193 serial samples for serum alpha-fetoprotein (AFP), CA 125, and CA 19-9 were analyzed, respectively. Six children with neonatal SCT developed eight recurrences. Serum AFP was elevated in two of two children prior to diagnosis of malignant recurrences (yolk sac tumor and adenocarcinoma), and CA 125 was elevated in one third of mature and one third of immature recurrences. CA 19-9 remained within reference values in relation to recurrences of neonatal SCT. Taken together, serum CA 125 measurements may complement the use of serum AFP in the follow-up of SCT.
Literature
1.
go back to reference Tapper D, Lack EE. Teratomas in infancy and childhood. A 54-year experience at the Children's Hospital Medical Center. Ann Surg. 1983;198:398–410.CrossRefPubMed Tapper D, Lack EE. Teratomas in infancy and childhood. A 54-year experience at the Children's Hospital Medical Center. Ann Surg. 1983;198:398–410.CrossRefPubMed
2.
go back to reference Woolley MM. Teratomas. In: Ashcraft KW, Holder TM, editors. Pediatric surgery. 2nd ed. Philadelphia: Saunders; 1993. p. 847–62. Woolley MM. Teratomas. In: Ashcraft KW, Holder TM, editors. Pediatric surgery. 2nd ed. Philadelphia: Saunders; 1993. p. 847–62.
3.
go back to reference Rescorla FJ, Sawin RS, Coran AG, Dillon PW, RGl A. Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Children’s Cancer Group. J Pediatr Surg. 1998;33:171–6.CrossRefPubMed Rescorla FJ, Sawin RS, Coran AG, Dillon PW, RGl A. Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Children’s Cancer Group. J Pediatr Surg. 1998;33:171–6.CrossRefPubMed
5.
go back to reference Lahdenne P, Heikinheimo M. Clinical use of tumor markers in childhood malignancies. Ann Med. 2002;34:316–23.CrossRef Lahdenne P, Heikinheimo M. Clinical use of tumor markers in childhood malignancies. Ann Med. 2002;34:316–23.CrossRef
6.
go back to reference Daoud E, Bodor G. CA-125 concentrations in malignant and nonmalignant disease. Clin Chem. 1991;37:1968–74.PubMed Daoud E, Bodor G. CA-125 concentrations in malignant and nonmalignant disease. Clin Chem. 1991;37:1968–74.PubMed
7.
go back to reference Bast Jr RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998;13:179–87.PubMed Bast Jr RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998;13:179–87.PubMed
8.
go back to reference Haglund C, Roberts PJ, Jalanko H, Kuusela P. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol. 1992;27:169–74.CrossRefPubMed Haglund C, Roberts PJ, Jalanko H, Kuusela P. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol. 1992;27:169–74.CrossRefPubMed
9.
go back to reference Lahdenne P, Pitkänen S, Rajantie J, Kuusela P, Siimes MA, Lanning M, et al. Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: developmental changes and use in pediatric germ cell tumors. Pediatr Res. 1995;38:797–801.CrossRefPubMed Lahdenne P, Pitkänen S, Rajantie J, Kuusela P, Siimes MA, Lanning M, et al. Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: developmental changes and use in pediatric germ cell tumors. Pediatr Res. 1995;38:797–801.CrossRefPubMed
10.
go back to reference Lahdenne P, Kuusela P, Siimes MA, Lanning M, Heikinheimo M. Biphasic reduction and concanavalin A binding properties of serum alpha-fetoprotein in preterm and term infants. J Pediatr. 1991;118:272–6.CrossRefPubMed Lahdenne P, Kuusela P, Siimes MA, Lanning M, Heikinheimo M. Biphasic reduction and concanavalin A binding properties of serum alpha-fetoprotein in preterm and term infants. J Pediatr. 1991;118:272–6.CrossRefPubMed
11.
go back to reference Aula P, Rapola J, Karjalainen O, Lindgren J, Hartikainen AL, Ml S. Prenatal diagnosis of congenital nephrosis in 23 high-risk families. Am J Dis Child. 1978;132:984–7.PubMed Aula P, Rapola J, Karjalainen O, Lindgren J, Hartikainen AL, Ml S. Prenatal diagnosis of congenital nephrosis in 23 high-risk families. Am J Dis Child. 1978;132:984–7.PubMed
12.
go back to reference Wald NJ, Cuckle HS, Boreham J, Stirrat GM, Turnbull AC. Maternal serum alpha-fetoprotein and low birth weight in relation to gestational age. Br J Obstet Gynaecol. 1982;89:216–7.PubMed Wald NJ, Cuckle HS, Boreham J, Stirrat GM, Turnbull AC. Maternal serum alpha-fetoprotein and low birth weight in relation to gestational age. Br J Obstet Gynaecol. 1982;89:216–7.PubMed
13.
go back to reference Huddart SN, Mann JR, Robinson K, Raafat F, Imeson J, Gornall P, et al. Children's Cancer Study Group. Sacrococcygeal teratomas: the UK Children's Cancer Study Group's experience. I Neonatal Pediatr Surg Int. 2003;19:47–51. Huddart SN, Mann JR, Robinson K, Raafat F, Imeson J, Gornall P, et al. Children's Cancer Study Group. Sacrococcygeal teratomas: the UK Children's Cancer Study Group's experience. I Neonatal Pediatr Surg Int. 2003;19:47–51.
14.
go back to reference Gabra HO, Jesudason EC, McDowell HP, Pizer BL, Losty PD. Sacrococcygeal teratoma—a 25-year experience in a UK regional center. J Pediatr Surg. 2006;41:1513–6.CrossRefPubMed Gabra HO, Jesudason EC, McDowell HP, Pizer BL, Losty PD. Sacrococcygeal teratoma—a 25-year experience in a UK regional center. J Pediatr Surg. 2006;41:1513–6.CrossRefPubMed
15.
go back to reference Draper H, Chitayat D, Ein SH, Langer JC. Long-term functional results following resection of neonatal sacrococcygeal teratoma. Pediatr Surg Int. 2009;25:243–6.CrossRefPubMed Draper H, Chitayat D, Ein SH, Langer JC. Long-term functional results following resection of neonatal sacrococcygeal teratoma. Pediatr Surg Int. 2009;25:243–6.CrossRefPubMed
16.
go back to reference Bilik R, Shandling B, Pope M, Thorner P, Weitzman S, Ein SH. Malignant benign neonatal sacrococcygeal teratoma. J Pediatr Surg. 1993;28:1158–60.CrossRefPubMed Bilik R, Shandling B, Pope M, Thorner P, Weitzman S, Ein SH. Malignant benign neonatal sacrococcygeal teratoma. J Pediatr Surg. 1993;28:1158–60.CrossRefPubMed
17.
go back to reference Salonen J, Leminen A, Stenman UH, Butzow R, Heikinheimo M, Heikinheimo O. Tissue AP-2gamma and Oct-3/4, and serum CA 125 as diagnostic and prognostic markers of malignant ovarian germ cell tumors. Tumour Biol. 2008;29:50–6.CrossRefPubMed Salonen J, Leminen A, Stenman UH, Butzow R, Heikinheimo M, Heikinheimo O. Tissue AP-2gamma and Oct-3/4, and serum CA 125 as diagnostic and prognostic markers of malignant ovarian germ cell tumors. Tumour Biol. 2008;29:50–6.CrossRefPubMed
18.
go back to reference Petäjä J, Pitkänen S, Vettenranta K, Fasth A, Heikinheimo M. Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. Clin Cancer Res. 2000;6:531–5.PubMed Petäjä J, Pitkänen S, Vettenranta K, Fasth A, Heikinheimo M. Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. Clin Cancer Res. 2000;6:531–5.PubMed
Metadata
Title
Tumor markers AFP, CA 125, and CA 19-9 in the long-term follow-up of sacrococcygeal teratomas in infancy and childhood
Authors
Satu-Liisa Pauniaho
Olga Tatti
Pekka Lahdenne
Harry Lindahl
Mikko Pakarinen
Risto Rintala
Markku Heikinheimo
Publication date
01-08-2010
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0026-8

Other articles of this Issue 4/2010

Tumor Biology 4/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine